Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial

AbstractObjectivesWe aimed to test our expectation that additional administration of Traditional Chinese medicine (TCM), maxingshigan-weijing decoction, is more effective in the management of COVID-19 patients compared to those treated with routine supportive care alone.Trial designThis is a multicenter, open-label 2-arm (1:1 ratio) randomized controlled trial.ParticipantsPatients will be recruited from 3 hospitals in Wenzhou China: the First Affiliated Hospital of Wenzhou Medical University, the Second Affiliated Hospital of Wenzhou Medical University and Wenzhou Center Hospital. The inclusion and exclusion criteria are as follows:Inclusion criteria1. Participants are 18-85 years of age, either male or female.2. Diagnosed as positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)3. Symptomatic. Mild (mild clinical symptoms without signs of pneumonia in chest X-ray) and Moderate (fever or respiratory symptom with signs of pneumonia in chest X-ray) .1. Signed the informed consent before treatment.2. Agreed not to enroll in any other clinical trials.3. InpatientsExclusion criteria1.< 18 or> 85 years old.2. Pregnancy and lactation.3. Serious heart, liver, kidney and hematopoietic system diseases, abnormal liver or kidney function.4. Suffering from other known virus pneumonia.5. Allergic to Chinese herbal medicine or suffering from allergies.6. Critical patients (respiratory failure treated by mechanical ventilation or shock or multiple organ failure).Inte...
Source: Trials - Category: Research Source Type: clinical trials